At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 18 enrolled
Drug / intervention
RBT-3drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1b Dose-escalating Study With RBT-3 in Healthy Volunteers and Volunteers With Chronic Kidney Disease Stage 3/4
In Brief
A Phase 1 clinical trial evaluating RBT-3 for Healthy Volunteers and Chronic Kidney Disease. Completed, enrolled 18 participants across 1 site.
Detailed Summary
This is a Phase 1b, single center, dose-escalating study evaluating the safety, tolerability, and pharmacodynamic effect of RBT-3 in healthy volunteers and in subjects with stage 3-4 chronic kidney disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Volunteers, Chronic Kidney Disease
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
20192020202120222023202420252026
Enrollment StartOct 2018
Primary CompletionMar 2019
Study CompletionAug 2019
First PostedAug 2019
TodayJul 2026
First PostedAug 28, 2019
Enrollment StartOct 21, 2018
Primary CompletionMar 31, 2019
Study CompletionAug 26, 2019
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 6.8 years ago
Interventions
RBT-3drug
intravenous administration